Literature DB >> 15525596

Contributions of the N- and C-terminal domains of IGF binding protein-6 to IGF binding.

Stephen J Headey1, Kerri S Leeding, Raymond S Norton, Leon A Bach.   

Abstract

Insulin-like growth factors IGF-I and IGF -II are important mediators of growth. A family of six high affinity IGF binding proteins (IGFBPs) modulate IGF action. IGFBPs have three domains, of which the N- and C-domains are involved in high affinity IGF binding. IGFBP-6 is unique in its 20-100-fold IGF-II binding specificity over IGF-I. The aim of this study was to determine the contributions of the N- and C-domains of IGFBP-6 to its IGF binding properties. We confirmed that differential dissociation kinetics are responsible for the IGF-II binding preference of IGFBP-6. The N-domain has rapid association kinetics, similar to full-length IGFBP-6, but both IGF-I and -II dissociate rapidly from this domain, thereby reducing its binding affinity for IGF-II approximately 50-fold. However, the N-domain binds IGF-I and -II with similar affinities and it has a similar IGF-I binding affinity to full-length IGFBP-6. This suggests that the C-domain confers the IGF-II binding preference of IGFBP-6; indeed, IGF-I bound inconsistently with very low affinity to the C-domain. Coincubation studies showed that isolated N- and C-domains of IGFBP-6 do not strongly cooperate to enhance IGF binding. The results of the binding studies are supported by the effects of the IGFBP-6 domains on IGF-induced colon cancer cell proliferation; the N-domain inhibited IGF-II induced proliferation with approximately 20-fold lower potency than IGFBP-6 and it was equipotent in inhibiting IGF-I- and IGF-II-induced proliferation. Coincubation of C-domain had no additional effect on N-domain-induced inhibition of proliferation. In conclusion, both the N- and C-domains of IGFBP-6 are involved in IGF binding, the C-domain is responsible for the IGF-II binding preference of IGFBP-6 and intact IGFBP-6 is necessary for high affinity IGF binding.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15525596     DOI: 10.1677/jme.1.01547

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  16 in total

1.  Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins.

Authors:  Tomasz Sitar; Grzegorz M Popowicz; Igor Siwanowicz; Robert Huber; Tad A Holak
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-21       Impact factor: 11.205

Review 2.  Molecular interactions in the insulin-like growth factor (IGF) axis: a surface plasmon resonance (SPR) based biosensor study.

Authors:  James Beattie; Kirsten Phillips; John H Shand; Malgorzata Szymanowska; David J Flint; Gordon J Allan
Journal:  Mol Cell Biochem       Date:  2007-09-25       Impact factor: 3.396

Review 3.  Defining the pathway to insulin-like growth factor system targeting in cancer.

Authors:  Steven A Rosenzweig; Hanudatta S Atreya
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

4.  Prohibitin-2 binding modulates insulin-like growth factor-binding protein-6 (IGFBP-6)-induced rhabdomyosarcoma cell migration.

Authors:  Ping Fu; Zhiyong Yang; Leon A Bach
Journal:  J Biol Chem       Date:  2013-09-03       Impact factor: 5.157

5.  Recent insights into the actions of IGFBP-6.

Authors:  Leon A Bach
Journal:  J Cell Commun Signal       Date:  2015-03-26       Impact factor: 5.782

Review 6.  IGF binding proteins in cancer: mechanistic and clinical insights.

Authors:  Robert C Baxter
Journal:  Nat Rev Cancer       Date:  2014-04-10       Impact factor: 60.716

Review 7.  Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis.

Authors:  James Beattie; Gordon J Allan; Jennifer D Lochrie; David J Flint
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

Review 8.  IGF-binding protein 2 is a candidate target of therapeutic potential in cancer.

Authors:  Xiaofeng Yao; Shanshan Sun; Xuan Zhou; Wenyu Guo; Lun Zhang
Journal:  Tumour Biol       Date:  2015-12-09

9.  Human Adipose Stem Cells (hASCs) Grown on Biodegradable Microcarriers in Serum- and Xeno-Free Medium Preserve Their Undifferentiated Status.

Authors:  Francesco Muoio; Stefano Panella; Valentin Jossen; Matias Lindner; Yves Harder; Michele Müller; Regine Eibl; Tiziano Tallone
Journal:  J Funct Biomater       Date:  2021-04-16

10.  Modeling the Insulin-Like Growth Factor System in Articular Cartilage.

Authors:  Lihai Zhang; David W Smith; Bruce S Gardiner; Alan J Grodzinsky
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.